A sprint to increase response to HCV treatment: Expectancies but caution-Reference-Cited by-同舟云学术

A sprint to increase response to HCV treatment: Expectancies but caution

Published:2011-11 Issue:5 Volume:55 Page:1154-1158
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Asselah Tarik

Publisher

Elsevier BV

Subject

Hepatology

Reference14 articles.

1. New direct-acting antiviral combination for the treatment of chronic hepatitis C;Asselah;Liver Int,2011

2. Boceprevir for untreated chronic HCV genotype 1 infection;Poordad;N Engl J Med,2011

3. Boceprevir for previously treated chronic HCV genotype 1 infection;Bacon;N Engl J Med,2011

4. Virologic response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin;Martinot-Peignoux;Antivir Ther,2009

5. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase 2 trial;Kwo;Lancet,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C Virus;Handbook of Pharmacogenomics and Stratified Medicine;2014

2. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation;Journal of Hepatology;2013-05

3. HCV infection: an enigma, recent advances and new paradigms for its treatment;Future Virology;2013-04

4. Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C;Clinical Therapeutics;2012-10

5. The aging patient with hemophilia;American Journal of Hematology;2012-03-19